Immunovant, Inc. IMVT R2K
Healthcare · Biotechnology · United States
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
READ MORE ›$33.30
+124.24% 1Y
Market & Price
Market Cap
$6.84B
Current Price
$33.30
High / Low (52W)
$35.56 / $14.69
Beta
0.70
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$4.85
Price to Book
6.87
P/S
-
EV/EBITDA
-11.14
Dividend Yield
-
Profitability & Returns
ROCE
-62.50%
ROE
-64.82%
ROA
-38.43%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.73
EPS (TTM)
$-2.77
Balance Sheet & Liquidity
Debt/Equity
0.01
Quick Ratio
8.68
Current Ratio
9.09
Debt
$72.00K
Total Assets
$957.01M
Current Assets
$948.82M
Working Capital
$844.40M
Ownership
Promoter Holding
56.76%
Chg in Prom Hold
-
FII / Inst Holding
54.74%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$5.93B
Total Revenue (TTM)
-
EBITDA
$-532.49M
Free Cash Flow
$-234.28M
Operating Cash Flow
$-407.31M
Shares Outstanding
205.31M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-46.56%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -46.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMVT Immunovant, Inc. R2K | 33.30 | - | $6.84B | - | -62.50% | -64.82% | - | -46.56% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2018 | Jul 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 113.83M | 127.22M | 131.76M | 114.36M | 159.55M |
| Operating Income | - | - | - | - | - | -92.34K | -419.76K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -113.83M | -127.22M | -131.76M | -114.36M | -159.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -113.72M | -127.12M | -131.66M | -114.26M | -159.46M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -105.87M | -119.70M | -125.91M | -109.08M | -150.70M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 583.00K | 913.00K | 594.00K | 1.55M | -2.84M |
| Net Income | -4.37M | -4.37M | -6.35M | -8.85M | -450 | -20.06M | -14.48M | -11.30M | -26.71M | -20.79M | -31.78M | -30.47M | -37.70M | -41.38M | -40.37M | -47.93M | -63.23M | -73.94M | -58.66M | -51.42M | -87.15M | - | - | -106.45M | -120.61M | -126.50M | -110.64M | -147.86M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.38 | -0.25 | -0.32 | -0.31 | -0.35 | -0.36 | -0.35 | -0.41 | -0.49 | -0.57 | -0.45 | -0.36 | -0.60 | - | - | -0.64 | -0.71 | -0.73 | -0.61 | -0.73 |
| R&D Expense | - | - | - | 7.68M | - | 18.48M | 10.33M | 4.95M | 16.92M | 11.98M | 21.09M | 18.70M | 21.36M | 29.76M | 28.43M | 37.74M | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 208.28M | 270.21M | 438.15M | 532.90M |
| Operating Income | - | - | - | - | -208.28M | -270.21M | -438.15M | -532.90M |
| EBITDA | - | - | - | - | -208.08M | -269.98M | -437.77M | -532.49M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -210.95M | -258.77M | -412.95M | -505.39M |
| Tax Provision | - | - | - | - | 9.00K | 567.00K | 891.00K | 215.00K |
| Net Income | -28.60M | -66.39M | -107.43M | - | -210.96M | -259.34M | -413.84M | -505.61M |
| Diluted EPS | - | - | -1.22 | -1.43 | -1.71 | -1.88 | -2.73 | - |
| R&D Expense | 25.73M | 47.93M | 68.60M | 101.81M | - | - | - | - |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -46.56% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +124.24% |
| 6 Months: | +39.04% |
| 3 Months: | +20.09% |
| 1 Month: | +23.56% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2018 | Jul 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 13.83M | 109.39M | 412.49M | - | 405.84M | 666.37M | 776.22M | 957.01M |
| Current Assets | - | - | - | - | - | - | 404.33M | 665.77M | 767.66M | 948.82M |
| Cash & Equivalents | - | - | 6.99M | 100.57M | 400.15M | - | 376.53M | 635.37M | 713.97M | 902.11M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 700.00K | 5.34M | 2.08M | 1.13M |
| Total Liabilities | - | - | 6.49M | 15.32M | 21.01M | - | 43.34M | 48.61M | 68.78M | 104.42M |
| Current Liabilities | - | - | - | 15.32M | 18.77M | - | 43.30M | 48.61M | 68.78M | 104.42M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 1.22M | 138.00K | 98.00K | 72.00K |
| Total Equity | -1.50M | -411.00K | 7.34M | 94.07M | 391.48M | - | 362.49M | 617.76M | 707.45M | 852.59M |
| Shares Outstanding | - | - | - | - | - | - | 130.33M | 145.58M | 170.11M | 203.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -28.55M | -53.36M | -83.33M | - | -188.19M | -214.23M | -375.87M | -407.31M |
| Investing Cash Flow | -52.00K | -31.00K | -210.00K | - | -197.00K | -360.00K | -759.00K | -8.00K |
| Financing Cash Flow | 35.58M | 146.97M | 383.11M | - | 70.89M | 472.43M | 454.49M | 595.76M |
| Capital Expenditure | -52.00K | -31.00K | -210.00K | - | -197.00K | -360.00K | -759.00K | -8.00K |
| Free Cash Flow | -28.60M | -53.39M | -83.54M | - | -188.39M | -214.59M | -376.63M | -407.32M |
| Net Change in Cash | - | - | - | - | -117.50M | 257.84M | 77.86M | 188.44M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | -389.7% | -70.6% | -27.4% | - | -58.2% | -42.0% | -58.5% | -59.3% |
| ROCE % | - | - | - | - | -57.4% | -43.7% | -61.9% | -62.5% |
Shareholding Pattern
Insiders
56.76%
Institutions
54.74%
Public Float
126.61%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 8.25% | 16.95M | $564.36M |
| 2 | Deep Track Capital, Lp | 5.61% | 11.53M | $383.85M |
| 3 | Blackrock Inc. | 3.20% | 6.57M | $218.93M |
| 4 | Baker Bros. Advisors, LP | 2.66% | 5.46M | $181.75M |
| 5 | State Street Corporation | 2.21% | 4.54M | $151.11M |
| 6 | TCG Crossover Management, LLC | 2.17% | 4.46M | $148.45M |
| 7 | Morgan Stanley | 1.89% | 3.88M | $129.10M |
| 8 | Vanguard Portfolio Management LLC | 1.80% | 3.70M | $123.37M |
| 9 | Vanguard Capital Management LLC | 1.76% | 3.62M | $120.55M |
| 10 | T. Rowe Price Investment Management, Inc. | 1.76% | 3.61M | $120.31M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMVT
No recent headlines available.